Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Transplantation and Cellular TherapyOpen Access

Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over time

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPhilipp MelhornNDNina DominikLRLina Rüsing

Discussion

Loading...

Member takes

Overview

Analysis of GvHD trials evaluates design characteristics and treatment trends, indicating a shift toward industry involvement and targeted therapies.

Key Points

  • This analysis aims to characterize treatment trials for graft-versus-host disease registered on ClinicalTrials.gov to identify trends in study features and results.
  • Screened 1,713 records to identify 384 trials meeting inclusion criteria.
  • Characterized phase distribution (15.9% phase 1, 38.8% phase 2, 11.2% phase 3).
  • Evaluated treatment types, designs, and endpoints over the past decade.
  • 61.1% of trials utilized single-group designs and most trials were sponsored by academic institutions (60.4%).
  • The most studied treatments included corticosteroids (64 trials) and mesenchymal stromal cells (52 trials).
  • A significant increase in industry sponsorship from 13.4% to 38.9% (p<0.001) and a shift towards targeted therapies were observed.

Cite This Study

Melhorn et al. (2026) studied this question.

synapsesocial.com/papers/6a36300ddb0793dc1a5375cfhttps://doi.org/10.1016/j.jtct.2026.06.023
View Full Paper
Ask AI
Bookmark
Share